Meng-Long Zhou1,2, Gui-Chao Li1,2, Wang Yang1,2, Wei-Juan Deng1,2, Ran Hu1,2, Yan Wang1,2, Zi-Wen Long2,3, Xiao-Wen Liu2,3, Ya-Nong Wang2,3, Zhen Zhang1,2. 1. 1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , PR China. 2. 2 Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , PR China. 3. 3 Department of Gastric Surgery, Fudan University Shanghai Cancer Center , Shangha , PR China.
Abstract
OBJECTIVE: The aim of this study was to compare the effects of adjuvant chemoradiotherapy (CRT) and adjuvant chemotherapy (ChT) on the survival of locally advanced gastric cancer (LAGC) patients treated with R1 resection. METHODS: The patients with LAGC and microscopically positive margins after a potentially curative gastrectomy in Fudan University Shanghai Cancer Centre were retrospectively identified. The patients who were referred to our hospital for adjuvant CRT after an R1 resection elsewhere were also included. The patients were divided into either the CRT group or ChT group according to the treatment strategy. We, then, examined the patient survival results and patterns of recurrence for each group. RESULTS: There were 114 LAGC patients treated with an R1 resection identified (CRT, n = 33; ChT, n = 81). The baseline characteristics between the two groups were not different. The estimated 3 year recurrence-free survival and overall survival in the CRT and ChT groups were 45.1% vs 31.8% (p = 0.09) and 49.6% vs 39.4% (p = 0.20), respectively. The results indicated that only nodal status was an independent prognostic factor (hazard ratio 4.04, 95% confidence interval 2.06-7.93). The risk of locoregional recurrence was increased in the ChT group. The subgroup analysis revealed that patients with pN0-2 GC showed a better recurrence-free survival due to adjuvant CRT (hazard ratio 0.19, 95% confidence interval 0.04-0.90; p = 0.022). CONCLUSION: Adjuvant CRT improves locoregional control and may benefit patients with pN0-2 GC after R1 resection. The nodal status may be the most important predictor for patient selection. Advances in knowledge: Nodal status may be the most important predictor for patient selection. Compared with adjuvant ChT, LAGC patients with pN0-2 disease may further benefit from additional radiotherapy after R1 resection.
OBJECTIVE: The aim of this study was to compare the effects of adjuvant chemoradiotherapy (CRT) and adjuvant chemotherapy (ChT) on the survival of locally advanced gastric cancer (LAGC) patients treated with R1 resection. METHODS: The patients with LAGC and microscopically positive margins after a potentially curative gastrectomy in Fudan University Shanghai Cancer Centre were retrospectively identified. The patients who were referred to our hospital for adjuvant CRT after an R1 resection elsewhere were also included. The patients were divided into either the CRT group or ChT group according to the treatment strategy. We, then, examined the patient survival results and patterns of recurrence for each group. RESULTS: There were 114 LAGC patients treated with an R1 resection identified (CRT, n = 33; ChT, n = 81). The baseline characteristics between the two groups were not different. The estimated 3 year recurrence-free survival and overall survival in the CRT and ChT groups were 45.1% vs 31.8% (p = 0.09) and 49.6% vs 39.4% (p = 0.20), respectively. The results indicated that only nodal status was an independent prognostic factor (hazard ratio 4.04, 95% confidence interval 2.06-7.93). The risk of locoregional recurrence was increased in the ChT group. The subgroup analysis revealed that patients with pN0-2 GC showed a better recurrence-free survival due to adjuvant CRT (hazard ratio 0.19, 95% confidence interval 0.04-0.90; p = 0.022). CONCLUSION: Adjuvant CRT improves locoregional control and may benefit patients with pN0-2 GC after R1 resection. The nodal status may be the most important predictor for patient selection. Advances in knowledge: Nodal status may be the most important predictor for patient selection. Compared with adjuvant ChT, LAGC patients with pN0-2 disease may further benefit from additional radiotherapy after R1 resection.
Authors: Johan L Dikken; Edwin P M Jansen; Annemieke Cats; Berdine Bakker; Henk H Hartgrink; Elma Meershoek-Klein Kranenbarg; Henk Boot; Hein Putter; Koen C M J Peeters; Cornelis J H van de Velde; Marcel Verheij Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Steven C Cunningham; Farin Kamangar; Min P Kim; Sommer Hammoud; Raqeeb Haque; Anirban Maitra; Elizabeth Montgomery; Richard E Heitmiller; Michael A Choti; Keith D Lillemoe; John L Cameron; Charles J Yeo; Richard D Schulick Journal: J Gastrointest Surg Date: 2005 May-Jun Impact factor: 3.452
Authors: Se Hoon Park; Tae Sung Sohn; Jeeyun Lee; Do Hoon Lim; Min Eui Hong; Kyoung-Mee Kim; Insuk Sohn; Sin Ho Jung; Min Gew Choi; Jun Ho Lee; Jae Moon Bae; Sung Kim; Seung Tae Kim; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Amy T Y Chang; Wai Tong Ng; Ada L Y Law; Ki Man Ku; Michael C H Lee; Anne W M Lee Journal: Gastric Cancer Date: 2011-02-17 Impact factor: 7.370
Authors: Lucy X Ma; Osvaldo Espin-Garcia; Charles H Lim; Di M Jiang; Hao-Wen Sim; Akina Natori; Bryan A Chan; Chihiro Suzuki; Eric X Chen; Geoffrey Liu; Savtaj S Brar; Carol J Swallow; Jonathan C Yeung; Gail E Darling; Rebecca K Wong; Sangeetha N Kalimuthu; James Conner; Elena Elimova; Raymond W Jang Journal: J Gastrointest Oncol Date: 2020-04